NFKB1 and breast carcinoma: A quite opposite effect of nandrolone was observed in MCF7 and MDA-MB-231 breast cancer cell lines, where nandrolone (at a concentration of 0.1 μM) inhibited their proliferation and migration by antagonizing the PI3K/Akt/NF-κB signaling pathway [43].